Clinical Trial Update: Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1 [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating persistence of antibodies and vaccine response to the meningococcal B recombinant vaccine in 4-year-old children; results completed and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease
• Meningococcal Meningitis

Drugs mentioned

• Bexsero (Meningococcal group B vaccine (4CMenB))

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningococcal Disease, Meningococcal Meningitis | Phase 3 | Status: COMPLETED | Results posted: 2015-01-13